Navigation Links
Valeant Pharmaceuticals Announces Private Exchange Offer
Date:3/29/2013

MONTREAL, March 29, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that its wholly owned subsidiary Valeant Pharmaceuticals International (the "Company") intends to commence an offer to exchange (the "Exchange Offer") any and all of its outstanding $500 million aggregate principal amount of 6.375% Senior Notes due 2020 (the "Existing Notes") for up to an additional $500 million aggregate principal amount of its 6.375% Senior Notes due 2020 (the "Exchange Notes") issued pursuant to the indenture, dated as of October 4, 2012 (the "Date of Issuance"), as supplemented, among the Company, Valeant Pharmaceuticals International, Inc. (the "Parent"), the guarantors named therein and The Bank of New York Mellon Trust Company, as trustee.

The Exchange Notes will be guaranteed by same guarantors of the Existing Notes, which are the Parent and each of the Parent's subsidiaries (other than the Company) that is a guarantor of the Parent's senior secured credit facilities. The form and terms of the Exchange Notes will be substantially identical to the form and terms of the Existing Notes.  The Company is conducting this Exchange Offer in order to satisfy its obligations under the indenture governing the Existing Notes with the anticipated result being that some or all of such notes will be part of a single series of notes under one indenture using a single CUSIP number.

Upon the terms and subject to the conditions of the Exchange Offer, for each $1,000 principal amount of Existing Notes validly tendered, and not withdrawn, in the Exchange Offer for the Existing Notes, eligible holders will receive $1,000 principal amount of Exchange Notes.

The Exchange Offer will expire at 5:00 p.m., New York City time, on April 26, 2013, unless extended or earlier terminated by t
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
2. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
3. Valeant Pharmaceuticals To Host Investor Day
4. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
5. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
6. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
7. Valeant Pharmaceuticals Announces Management Change
8. Valeant Pharmaceuticals To Syndicate Incremental Loans
9. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
10. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
11. Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its Israeli ... sophisticated agro-breeding solutions for plant breeders and researchers, today ... of directors appointed chemistry and pharmaceutical industry expert Dr. ... the board. From 1975 to 2012, Dr. ...
(Date:1/15/2014)... BOSTON , Jan. 15, 2014 Tegra Medical is ... Mark King as its new Chief Executive Officer.  Mark ... in which he has overseen the company,s four facilities in ... and Costa Rica.  Mr. King joined Tegra Medical in 2012 ...
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness & ... Center by the Medical Fitness Association, a non-profit organization ... their full potential. The Cadence Fitness & Health Center ... suburbs and second in the Chicagoland area. ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... Preclinical findings of amylin/leptin synergy and translational Phase 2A, ... of the National ... States of America, SAN DIEGO, May 5 ... initiation of a Phase 2B clinical study,evaluating various dosing ...
... BETHESDA, Md., May 5 Vaccines don,t just keep ... who can earn,higher wages and save more money, according ... Harvard School of Public Health., Bloom, who has ... be the keynote speaker at the 11th Annual Conference ...
Cached Medicine Technology:Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity 2Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity 3Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity 4Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity 5Annual Conference on Vaccine Research to Highlight Not Only Health Benefits But Also Economic Gains 2Annual Conference on Vaccine Research to Highlight Not Only Health Benefits But Also Economic Gains 3Annual Conference on Vaccine Research to Highlight Not Only Health Benefits But Also Economic Gains 4Annual Conference on Vaccine Research to Highlight Not Only Health Benefits But Also Economic Gains 5Annual Conference on Vaccine Research to Highlight Not Only Health Benefits But Also Economic Gains 6
(Date:7/10/2014)... Estonian-born Katerina Alba,s research at the University of Huddersfield ... the most popular emulsion-based food products such as ... is starting to gain an international profile for her ... and food science at the University and now she ... with her supervisor, Dr Vassilis Kontogiorgos, she is investigating ...
(Date:7/10/2014)... A neuroscientist at Rutgers University-Newark says the human brain ... a finding that could provide a better understanding ... conditions that afflict an estimated 13.6 million Americans. , ... , Michael Cole, an assistant professor at the Center ... brain architecture of a person at rest is basically ...
(Date:7/10/2014)... sarcomas research group at the Bellvitge Biomedical Research Institute ... been tested in 19 patients a new therapeutic combination ... indicate that the new treatment could stabilize the growth ... the British Journal of Cancer ., Sarcomas ... complex since there are several subtypes. It can affect ...
(Date:7/10/2014)... 10, 2014) Men who experience hot flashes are ... find relief from their silent suffering if they ... findings from a Baylor University case study., After seven ... had uncontrolled hot flashes following prostate cancer surgery showed ... also an impressive improvement in sleep quality, according to ...
(Date:7/9/2014)... that sudden, acute episodes of low back pain are ... air pressure, wind direction and precipitation. Findings published in ... the American College of Rheumatology (ACR), indicate that the ... wind speed or wind gusts, but was not clinically ... (WHO) nearly everyone experiences low back pain at some ...
Breaking Medicine News(10 mins):Health News:World interest in research work on the benefits of the Okra plant 2Health News:Working to loosen the grip of severe mental illness 2Health News:New therapeutic combination to slow resistant sarcomas 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 3Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 4Health News:Low back pain? Don't blame the weather 2
... might spur obesity, German study finds , FRIDAY, Aug. 7 ... financial debt, German researchers suggest. , In their study, Eva ... the weight of more than 9,000 people. , They found ... debt were classified as obese, a full quarter of those ...
... , , CENTENNIAL, Colo., Aug. 7 ... and soft tissue allografts for use in surgical procedures, announced today that ... in the Healthcare category of the Top Company awards program hosted by ... is hosting the business awards program for the 22nd consecutive year. ...
... , , , ... WCRX ) today announced its results for the quarter ... 2009 increased 7.1% to $250.8 million over the prior year quarter. ... sales of DORYX, LOESTRIN 24 FE and ESTRACE Cream which were ...
... ... onsite employee health services and technology solutions, today announced the opening of a Chicago field ... region. , ... August 7, 2009 -- Marathon Health, a leading provider of onsite employee health services ...
... and most expensive patients need fewer health care resources and ... nurse-physician primary care team that tracks their health and offers ... Johns Hopkins Bloomberg School of Public Health. The research, published ... that in the first eight months of a randomized controlled ...
... rate of heart attack, tripled rate of death seen ... New research shows that men diagnosed with the chest ... neither artery-opening angioplasty nor coronary-bypass surgery reduced long-term mortality ... newly diagnosed with angina at 40 primary-care practices in ...
Cached Medicine News:Health News:Slide Into Debt Could Bring Wider Waistline 2Health News:AlloSource Chosen as Healthcare Finalist in 2009 'Top Companies' 2Health News:AlloSource Chosen as Healthcare Finalist in 2009 'Top Companies' 3Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 2Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 3Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 4Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 5Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 6Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 7Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 8Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 9Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 10Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 11Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 12Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 13Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 14Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 15Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 16Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 17Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 18Health News:Marathon Health Expands Midwest Presence 2Health News:Guided care reduces cost of health care for older persons with chronic conditions 2Health News:Men With Angina Do Worse Than Women 2Health News:Men With Angina Do Worse Than Women 3
1% tryptone, 0.5% yeast extract, 1.0% Sodium Chloride. 1.5% agararose...
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
... flowing powder. pH: pH(4.7%, H 2 O): ... Yeast Extract: 47% Potassium Phosphate Dibasic: 25% Potassium ... 47 gm powder per liter of purified water. ... and recombinant proteins than LB media by allowing ...
1.2% Tryptone, 2.4% Yeast Extract, 0.4% Glycerol, with 100ml of 10x Phosphate buffer supplement (0190-01)....
Medicine Products: